Skip to main content

Table 4 Antibiotic and antimycotic treatment among 71 of 162 hospitalized SARS-CoV-2 patients

From: Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Medication (ATC code)

All (n = 162)a

Non-ICU (n = 121)

ICU-patients (n = 41)

n (%)

n (%)

n (%)

One or more antibiotic or antifungal treatments

71/162 (43.8)

35/121 (28.9)

36/41 (87.8)

Penicillins +/- beta-lactamase inhibitors

 Amoxicillin (J01CA04)

1 (0.6)

0

1 (2.4)

 Amoxicillin and clavulanic acid (J01CR02)

36 (22.2)

18 (14.9)

18 (43.9)

 Piperacillin/tazobactam (J01CR05)

30 (18.5)

10 (8.3)

20 (48.8)

Carbapenems

 Meropenem (J01DH02)

16 (9.9)

1 (0.8)

15 (36.6)

 Imipenem (J01DH51)

1 (0.6)

0

1 (2.4)

Cefalosporins

 Ceftriaxone (J01DD04)

14 (8.6)

8 (6.6)

6 (14.6)

 Cefepime (J01DE01)

4 (2.5)

1 (0.8)

3 (7.3)

 Cefazolin (J01DB04)

1 (0.6)

0

1 (2.4)

Quinolones

 Ciprofloxacin (J01MA02)

1 (0.6)

1 (0.8)

0

Sulfonamides with trimethoprim

 Sulfamethoxazole with trimethoprim (J01EE01)

3 (1.9)

2b (1.7)

1 (2.4)

Aminoglycosides

 Tobramycin (J01GB01)

1 (0.6)

0

1 (2.4)

Polymyxines

 Colistin (J01XB01)

1 (0.6)

0

1 (2.4)

Glycopeptides

 Vancomycin (J01XA01)

2 (1.2)

2c (1.7)

0

Other antibacterials

 Daptomycin (J01XX09)

3 (1.9)

0

3 (7.3)

Antimycotics

 Fluconazole (J02AC01)

1 (1.2)

0

1 (2.4)

 Caspofungin (J02AX04)

3 (1.9)

1 (0.8)

2 (4.9)

 Anidulafungin (J02AX06)

1 (0.6)

0

1 (2.4)

 Voriconazole (J02AC03)

2 (1.2)

0

2 (4.9)

  1. Only treatment administered more than 24 h was considered as relevant
  2. aSeveral patients received one or more antibiotics
  3. bSulfamethoxazole with trimethoprim was administered as prophylaxis in immunocompromised patients
  4. cVancomycin was administered peroral for treatment of Clostridioides difficile infection